Wegovy® – the weight-loss drug sparking a global race to end obesity
Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so.
Wegovy® is a chronic weight management drug, available only via prescription. Novo Nordisk advocates that obesity is a chronic and severely misunderstood disease, one that they are committed to working towards developing innovative therapies, and to increasing awareness and understanding for, and defeating stigma.
The remarkable popularity of the drug has prompted some analysts to predict a weight-loss market reaching $100 billion a year or more by the end of the decade.
The weight loss drug was also approved for use in adolescents aged 12-17 in December 2022. Since then, the demand for the treatment has markedly increased, along with some controversy over the suitability of giving teens a weight loss drug. However, regulatory bodies and Novo Nordisk state that the medication is safe for use and always under prescription from a doctor.
As the growth in demand for the treatment continues, Novo Nordisk has put in place measures to ensure the supply will meet this demand after running into supply difficulties in 2023 as demand outstripped their manufacturing capacity. Now, with the rollout of more than double the lower dosage forms of Wegovy® in the USA, more people will be able to start treatment in 2024. Novo Nordisk will continue to increase the supply over the course of the year.
Novo Nordisk will be able to meet the demand for their blockbuster therapy through their holding company – Novo Holdings – recent acquisition of US-based biotech and pharma CDMO Catalent in a US$16.5 billion deal.
The acquisition will mean the company will have increased capacity to produce Wegovy® and Ozempic® (another semaglutide GLP-1 receptor agonist produced by Novo Nordisk as a Type 2 diabetes treatment).
Lars Fruergaard Jørgensen, President and CEO at Novo Nordisk, commented: “We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future.”
In February 2024 the weight-loss drug, approved for prescription use in Japan, started sales. Concurrently, the health ministry in Japan released use-guidelines for Wegovy®, urging people not to use it other than for obesity treatment and that it should be prescribed with caution, only to patients of a high need.
The highly-sort after medication is now looking to be replicated in other countries, with the pharma market in India keen to keep up. Several top generics makers in the country, including Sun Pharma, Dr Reddy's, and Lupin, among others have set to work on their on versions of the therapy.
As Novo Nordisk aren’t expected to release Wegovy® in India until 2026 the developments from India-based drug makers could go a long way to increasing accessibility to the treatment.
In the USA, Eli Lily – maker of weight-loss drugs Zepbound and Mounjaro – has also been struggling to meet the demand, showing a gap in the market that other companies are racing to fill.
See more on what the Novo – Catalent deal means for the pharmaceutical industry by clicking the button below.
Sources
Novo Nordisk. Updates about Wegovy®. [Date accessed 26/02/2024] www.novonordisk-us.com/supply-update.html
The Guardian. Novo Nordisk parent buys US drug firm for $16.5bn to expand Wegovy supply. [Date accessed 26/02/2024] www.theguardian.com/business/2024/feb/05/novo-nordisk-us-drug-firm-wegovy-catalent-weight-loss
NHK World-Japan. Prescription for obesity treatment drug Wegovy begins in Japan. [Date accessed 26/02/2024] www3.nhk.or.jp/nhkworld/en/news/20240222_34/
Reuters. India pharma companies develop versions of Wegovy to get in on weight-loss windfall. [Date accessed 26/02/2024] www.reuters.com/business/healthcare-pharmaceuticals/india-pharma-companies-develop-versions-wegovy-get-weight-loss-windfall-2024-02-22/
Related News
-
News US FDA approves three different oncology drugs in 1 week
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. -
News What the Novo Holdings and Catalent deal means for pharma outsourcing
On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing.... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Novo Holdings buys CDMO Catalent in US$16.5 billion deal
Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk. -
News Special Edition Women in Pharma: International Day of Women and Girls in Science
In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. -
News Pharmapack Awards 2024 Start-up Innovation Award Winner – Capa Valve Ltd
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance